18.8K
Articles
720.6K
Citations
3.1
avg. Impact Factor
316
h-index

Most Cited Articles of Department of Gynecologic Oncology and Reproductive Medicine in 2022

TitleJournalYearCitations
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.New England Journal of Medicine202288
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.New England Journal of Medicine202230
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.New England Journal of Medicine202218
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.Leukemia202215
Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors.Science Translational Medicine202211
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.The Lancet Gastroenterology and Hepatology202210
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.Annals of Oncology202210
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.Cancer Cell202210
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study.Molecular Cancer20229
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.JAMA Oncology20227
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.Lancet, The20227
Investigational antifungal agents for invasive mycoses: a clinical perspective.Clinical Infectious Diseases20226
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.Blood20225
Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association.Nature Communications20225
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.Lancet Oncology, The20225
Clinical challenges treating infections: an update.JAC-Antimicrobial Resistance20225
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.Gastroenterology20225
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer.Nature Communications20225
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors.Science Advances20225
Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung AdenocarcinomaCancers20225
Clear cell carcinoma of the endometrium.Gynecologic Oncology20224
Myocardial Rev-erb-Mediated Diurnal Metabolic Rhythm and Obesity Paradox.Circulation20224
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.Journal of Clinical Oncology20224
Impact of early palliative care according to baseline symptom severity: Secondary analysis of a cluster-randomized controlled trial in patients with advanced cancer.Cancer Medicine20224
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.Cancers20224